Shanghai Junshi Biosciences Co Ret. on equity
What is the Ret. on equity of Shanghai Junshi Biosciences Co?
The Ret. on equity of Shanghai Junshi Biosciences Co., Ltd. is -26.16%
What is the definition of Ret. on equity?
Return on equity is a measure of the profitability of a business in relation to the book value of the shareholder equity. It is computed by dividing fiscal year net income by total shareholder equity.
ttm (trailing twelve months)
The return on equity (ROE) ROE is a measure of how well a company uses investments to generate earnings growth. ROE is used for comparing the performance of companies in the same industry. It indicated the management's ability to generate income from the equity available to it. ROEs of 15-20% are generally considered good. ROEs are also a factor in stock valuation, in association with other financial ratios. In general, stock prices are influenced by earnings per share (EPS), so that stock of a company with a 20% ROE will generally cost twice as much as one with a 10% ROE.
Ret. on equity of companies in the Health Care sector on OTC compared to Shanghai Junshi Biosciences Co
What does Shanghai Junshi Biosciences Co do?
Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in the therapeutic areas of oncology, metabolic, autoimmune, neurologic, and infectious diseases in the People's Republic of China. The company offers JS001, a recombinant humanized anti-PD-1 monoclonal antibody under the trade name of TUOYI for the indication of melanoma, mucosal melanoma, soft tissue sarcoma, nasopharyngeal carcinoma, urothelial carcinoma, non-small cell lung carcinoma, triple negative breast carcinoma, esophageal squamous cell carcinoma, and hepatocellular carcinoma. It is also developing UBP1211, a biosimilar of Humira for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriasis; JS002, a recombinant humanized anti-PCSK9 monoclonal antibody for treating hyperlipidemia; UBP1213, a recombinant humanized anti-BLyS monoclonal antibody for injection. In addition, the company is developing JS501, a biosimilar of Avastin; and JS003, a recombinant humanized anti-PD-L1 monoclonal antibody for injection; JS101, a pan-CDK inhibitor; TAB004/JS004, a recombinant humanized anti-BTLA monoclonal antibody for injection; and JS005, a recombinant humanized anti-IL-17A monoclonal antibody for injection. It has an agreement with Eli Lilly and Company to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, the disease caused by the SARS-CoV-2 novel coronavirus as well as Coherus Biosciences, Inc. for the development and commercialization of toripalimab, Junshi Biosciences' anti-PD-1 antibody. Shanghai Junshi Biosciences Co., Ltd. was founded in 2012 and is headquartered in Shanghai, People's Republic of China.
Companies with ret. on equity similar to Shanghai Junshi Biosciences Co
- Luminex Resources has Ret. on equity of -26.26%
- Directel has Ret. on equity of -26.25%
- FYI Resources has Ret. on equity of -26.22%
- Dorel Industries has Ret. on equity of -26.21%
- Justify Capital has Ret. on equity of -26.19%
- AuKing Mining has Ret. on equity of -26.18%
- Shanghai Junshi Biosciences Co has Ret. on equity of -26.16%
- Chariot Oil & Gas has Ret. on equity of -26.16%
- Starpharma has Ret. on equity of -26.13%
- Ted Baker Plc has Ret. on equity of -26.12%
- Eaton Vance Enhanced Equity Income Fund II has Ret. on equity of -26.12%
- CGX has Ret. on equity of -26.11%
- Lee Hing Development has Ret. on equity of -26.10%